{
    "nctId": "NCT04609540",
    "briefTitle": "Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC",
    "officialTitle": "Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer, Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Progression free survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* woman, age \\> 18 years old\n* Diagnosed with HER2 +Metastatic Breast Cancer\n* Pyrotinib Combined With Trastuzumab And Chemotherapy for at least one cycle, starting from 2020.11.01-2021.10.31\n* Available medical history\n\nExclusion Criteria:\n\n* Incomplete medical history",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}